Immunoglobulin-Based Support in Primary and Secondary Immunodeficiency
Research activity includes human normal immunoglobulin therapies for patients with weakened immune function, with attention to preventing serious bacterial and major infections in settings such as hypogammaglobulinemia and secondary immunodeficiency.
- Intravenous immunoglobulin and subcutaneous immunoglobulin replacement
- Serious bacterial infection prevention
- Hypogammaglobulinemia management
These studies extend to patients receiving B-cell depletion therapy and those with immune dysfunction linked to chronic lymphocytic leukemia.
Autoimmune and Rheumatic Disease-Associated Infection Prevention
Clinical research also focuses on infection prevention in individuals with autoimmune and rheumatic conditions who have reduced immune protection during treatment.
- B-cell depletion therapy-associated infection risk
- Major infection prevention
- Immune deficiency in autoimmune disease
The therapeutic interest centers on maintaining immune support in patients whose underlying disease or treatment increases vulnerability to infection.
Pediatric Neuropsychiatric Conditions
One area of investigation involves pediatric acute-onset neuropsychiatric syndrome, with clinical interest in reducing symptom severity in affected children and adolescents.
- PANS
- Pediatric symptom control
- Neuropsychiatric disorder management
This work places immunologic therapy within a pediatric neuroinflammatory context.
Hereditary Angioedema and C1 Esterase Inhibitor Therapy
Research includes treatment of acute hereditary angioedema attacks in adolescents and adults, with focus on C1 esterase inhibitor-based intervention for acute symptom relief and procedure-related prevention.
- Congenital C1-INH deficiency
- Acute angioedema attack treatment
- Attack prevention in hereditary angioedema
The therapeutic scope addresses complement-mediated swelling disorders requiring targeted plasma-derived replacement therapy.
